论文部分内容阅读
目的:研究CD151在肝细胞癌组织中的表达并探讨其临床意义。方法:收集肝细胞癌手术组织标本42例,20例癌旁正常组织作为对照,采用qRT-PCR检测肝细胞癌组织及对照组织中CD151的表达情况,分析CD151表达水平与肝细胞癌临床病理参数之间的关系。结果:肝细胞癌组织中CD151平均表达量明显高于癌旁对照组织,差异具有统计学意义,癌旁对照组织中CD151平均表达量约为肝细胞癌的2.90倍。CD151的表达水平与肝细胞癌恶性程度、肿瘤分化程度以及AFP表达有关,CD151的表达水平与肝细胞癌患者年龄、性别、HBsAg、肿瘤大小、是否合并肝硬化等无关。结论:CD151与肝细胞癌的发生、临床进展密切相关,它可能是肝细胞癌新的潜在的治疗靶点及诊断预后分子标志物。
Objective: To study the expression of CD151 in hepatocellular carcinoma and its clinical significance. Methods: 42 cases of hepatocellular carcinoma (HCC) were collected and 20 cases of adjacent normal tissues were collected as control. The expression of CD151 in hepatocellular carcinoma tissues and control tissues was detected by qRT-PCR. The expression of CD151 in hepatocellular carcinoma tissues was compared with the clinicopathological parameters The relationship between. Results: The average expression of CD151 in hepatocellular carcinoma was significantly higher than that in adjacent non-cancerous tissues. The difference was statistically significant. The average expression of CD151 in cancer adjacent tissues was about 2.90 times that of hepatocellular carcinoma. The expression level of CD151 was correlated with the degree of malignancy of hepatocellular carcinoma, the degree of tumor differentiation and the expression of AFP. The expression level of CD151 was not associated with the age, sex, HBsAg, tumor size, cirrhosis or not in patients with hepatocellular carcinoma. Conclusion: CD151 is closely related to the occurrence and clinical progress of hepatocellular carcinoma. It may be a new potential therapeutic target for hepatocellular carcinoma and a molecular marker for diagnosis and prognosis.